Search Within

Andrew D Seidman

  1. "Shanu Modi"
Formats
  1. Journal Article (15)
  2. Meeting Abstract (13)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (29)
  2. Department of Medicine (29)
  3. Solid Tumor Oncology Division (29)
  4. Survivorship Research (23)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (22)
  6. Epidemiology and Biostatistics (19)

More Groups

People
  1. Shanu Modi (29)
  2. Larry Norton (18)
  3. Clifford Hudis (16)
  4. Chau Dang (14)
  5. Gabriella D'Andrea-Carlino (10)
  6. Mark Robson (10)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (2)
  5. 2021 (1)
  6. 2018 (1)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (5)
  3. Clinical Breast Cancer (4)
  4. npj Breast Cancer (3)
  5. Annals of Oncology (2)
  6. International Journal of Radiation Oncology, Biology, Physics (2)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. Elsevier Inc. (7)
  3. American Society of Clinical Oncology (5)
  4. Nature Publishing Group (3)
  5. Oxford University Press (2)
  6. Springer (2)

More Publishers

Results (29)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save